ArticleNuclear medicine and biology
Matched-pair,
Article in Nuclear medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- A Siderophore-Antibiotic Heterodimer Imaging Agent EnablesJournal of medicinal chemistry · 2026Article
- A true theranostic pair -European journal of nuclear medicine and molecular imaging · 2026Article
- Preclinical Evaluation of aACS pharmacology & translational science · 2026Article
- Bispecific Radioligands (BRLs): Two Is Better Than One.Journal of clinical medicine · 2025Review
- Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine-Glycine-Aspartate) Strategies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Carrier systems of radiopharmaceuticals and the application in cancer therapy.Cell death discovery · 2024Review
- The effects of novel macrocyclic chelates on the targeting properties of theEJNMMI research · 2023Article
- Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling.RSC medicinal chemistry · 2023Review
- Multimeric RGD-Based Strategies for Selective Drug Delivery to Tumor Tissues.Pharmaceutics · 2023Review
- Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Article
- Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy.Pharmaceuticals (Basel, Switzerland) · 2020Review
- New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer.Frontiers in chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
introductionIn this study, we describe development of a true matched-pair theranostic agent that is able to target the α
methodsWe have previously described the development of [RGD-Glu-6Ahx-RM2] (where RGD: Arg-Gly-Asp; Glu: glutamic acid; 6-Ahx: 6-amino hexanoic acid; RM2: (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2)) that has been conjugated to a DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) bifunctional chelating agent (BFCA) to afford [RGD-Glu-[DO3A]-6-Ahx-RM2] peptide. In this study, we have radiolabeled [RGD-Glu-[DO3A]-6-Ahx-RM2] peptide with
resultsCompetitive displacement binding assays in PC-3 cells showed high binding affinity for the GRPR (IC
conclusionsThe [RGD-Glu-[[ ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE: The theranostic, heterobivalent, agents described herein perform comparably with other mono- and multivalent conjugates we have reported and offer the potential of improved sensitivity for detecting prostate cancer cells that might exhibit differing profiles of receptor expression on tumor cells in human patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.